Evidence map›Paper›PMID 26994919›Full record

ArticleBiochimica et biophysica acta2016

Wide tolerance to amino acids substitutions in the OCTN1 ergothioneine transporter.

Marta Frigeni, Francesco Iacobazzi, Xue Yin, Nicola Longo

Abstract read
In one paragraph

Article in Biochimica et biophysica acta, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Reumatologia · 2019
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Marta FrigeniDivision of Medical Genetics, Departments of Pediatrics and Pathology, University of Utah, Salt Lake City, UT 84108, United States.
Francesco IacobazziDivision of Medical Genetics, Departments of Pediatrics and Pathology, University of Utah, Salt Lake City, UT 84108, United States; Department of Basic Medical Sciences, University of Bari, Policlinico, I-70124 Bari, Italy.
Xue YinDivision of Medical Genetics, Departments of Pediatrics and Pathology, University of Utah, Salt Lake City, UT 84108, United States.
Nicola LongoDivision of Medical Genetics, Departments of Pediatrics and Pathology, University of Utah, Salt Lake City, UT 84108, United States. Electronic address: Nicola.Longo@hsc.utah.edu.
University of Utah · US

Funding

THE CARNITINE TRANSPORTER IN HUMAN DISEASER01DK053824 · NIDDK · UNIVERSITY OF UTAH · PI LONGO, NICOLA · 2000 to 2010
$2.3M
NIDDK NIH HHS DK053824NIDDK NIH HHS R01 DK053824
6 · The paper itself

Abstract

backgroundOrganic cation transporters transfer solutes with a positive charge across the plasma membrane. The novel organic cation transporter 1 (OCTN1) and 2 (OCTN2) transport ergothioneine and carnitine, respectively. Mutations in the SLC22A5 gene encoding OCTN2 cause primary carnitine deficiency, a recessive disorders resulting in low carnitine levels and defective fatty acid oxidation. Variations in the SLC22A4 gene encoding OCTN1 are associated with rheumatoid arthritis and Crohn disease.

methodsHere we evaluate the functional properties of the OCTN1 transporter using chimeric transporters constructed by fusing different portion of the OCTN1 and OCTN2 cDNAs. Their relative abundance and subcellular distribution was evaluated through western blot analysis and confocal microscopy.

resultsSubstitutions of the C-terminal portion of OCTN1 with the correspondent residues of OCTN2 generated chimeric OCTN transporters more active than wild-type OCTN1 in transporting ergothioneine. Additional single amino acid substitutions introduced in chimeric OCTN transporters further increased ergothioneine transport activity. Kinetic analysis indicated that increased transport activity was due to an increased V(max), with modest changes in K(m) toward ergothioneine.

conclusionsOur results indicate that the OCTN1 transporter is tolerant to extensive amino acid substitutions. This is in sharp contrast to the OCTN2 carnitine transporter that has been selected for high functional activity through evolution, with almost all substitutions reducing carnitine transport activity. GENERAL SIGNIFICANCE: The widespread tolerance of OCTN1 to amino acid substitutions suggests that the corresponding SLC22A4 gene may have derived from a recent duplication of the SLC22A5 gene and might not yet have a defined physiological role.

Indexed as

Amino Acid SubstitutionAnimalsBiological TransportBlotting, WesternCHO CellsCricetulusErgothioneineHumansMicroscopy, ConfocalOrganic Cation Transport ProteinsStructure-Activity RelationshipSymportersErgothioneineOrganic Cation Transport ProteinsSLC22A4 protein, humanSymportersErgothioneine transportOCTN1OCTN2Organic cation transportersSLC22A4SLC22A5

Identifiers

PMID26994919
PMCPMC4838292
OpenAlexW2297089508

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.